TITLE

Effectiveness of second generation antipsychotics: A systematic review of randomized trials

AUTHOR(S)
Johnsen, Erik; Jørgensen, Hugo
PUB. DATE
January 2008
SOURCE
BMC Psychiatry;2008, Vol. 8, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Systematic reviews based on efficacy trials are inconclusive about which second generation antipsychotic drug (SGA) should be preferred in normal clinical practice, and studies with longer duration and more pragmatic designs are called for. Effectiveness studies, also known as naturalistic, pragmatic, practical or real life studies, adhere to these principles as they aim to mimic daily clinical practice and have longer follow-up. Objective: To review the head-to-head effectiveness of SGAs in the domains of global outcomes, symptoms of disease, and tolerability. Methods: Searches were made in Embase, PubMED, and the Cochrane central register of controlled trials for effectiveness studies published from 1980 to 2008, week 1. Different combinations of the keywords antipsychotic*, neuroleptic* AND open, pragmatic, practical, naturalistic, real life, effectiveness, side effect*, unwanted effect*, tolera* AND compar* AND random* were used. Results: Sixteen different reports of randomized head-to-head comparisons of SGA effectiveness were located. There were differences regarding sample sizes, inclusion criteria and follow-up periods, as well as sources of financial sponsorship. In acute-phase and first-episode patients no differences between the SGAs were disclosed regarding alleviating symptoms of disease. Olanzapine was associated with more weight gain and adverse effects on serum lipids. In the chronic phase patients olanzapine groups had longer time to discontinuation of treatment and better treatment adherence compared to other SGAs. The majority of studies found no differences between the SGAs in alleviating symptoms of psychosis in chronically ill patients. Olanzapine was associated with more metabolic adverse effects compared to the others SGAs. There were surprisingly few between-drug differences regarding side effects. First generation antipsychotics were associated with lower total mental health care costs in 2 of 3 studies on chronically ill patients, but were also associated with more extrapyramidal side effects compared to the SGAs in several studies. Conclusion: In chronically ill patients olanzapine may have an advantage over other SGAs regarding longer time to treatment discontinuation and better drug adherence, but the drug is also associated with more metabolic side effects. More effectiveness studies on first-episode psychosis are needed.
ACCESSION #
35702786

 

Related Articles

  • Noise and health in vulnerable groups: A review. van Kamp, Irene; Davies, Hugh // Noise & Health;May/Jun2013, Vol. 15 Issue 64, p153 

    Vulnerable or susceptible groups are mentioned in most reviews and documents regarding noise and health. But only a few studies address this issue in a concrete and focused way. Groups at risk most often mentioned in the literature are children, the elderly, the chronically ill and people with a...

  • Uncovering Treatment Burden as a Key Concept for Stroke Care: A Systematic Review of Qualitative Research. Gallacher, Katie; Morrison, Deborah; Jani, Bhautesh; Macdonald, Sara; May, Carl R.; Montori, Victor M.; Erwin, Patricia J.; Batty, G. David; Eton, David T.; Langhorne, Peter; Mair, Frances S. // PLoS Medicine;Jun2013, Vol. 10 Issue 6, p1 

    Background: Patients with chronic disease may experience complicated management plans requiring significant personal investment. This has been termed 'treatment burden' and has been associated with unfavourable outcomes. The aim of this systematic review is to examine the qualitative literature...

  • Association between Drug Insurance Cost Sharing Strategies and Outcomes in Patients with Chronic Diseases: A Systematic Review. Mann, Bikaramjit S.; Barnieh, Lianne; Tang, Karen; Campbell, David J. T.; Clement, Fiona; Hemmelgarn, Brenda; Tonelli, Marcello; Lorenzetti, Diane; Manns, Braden J. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Prescription drugs are used in people with hypertension, diabetes, and cardiovascular disease to manage their illness. Patient cost sharing strategies such as copayments and deductibles are often employed to lower expenditures for prescription drug insurance plans, but the impact on...

  • The Clinical Effectiveness of Patient Initiated Clinics for Patients with Chronic or Recurrent Conditions Managed in Secondary Care: A Systematic Review. Whear, Rebecca; Abdul-Rahman, Abdul-Kareem; Boddy, Kate; Thompson-Coon, Jo; Perry, Mark; Stein, Ken // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background: Missed or inappropriate hospital appointments cost the UK National Health Service millions of pounds each year and delay treatment for other patients. Innovative methods of appointment scheduling that are more flexible to patient needs, may improve service quality and preserve...

  • Low-glycaemic index diets in the management of blood lipids: a systematic review and meta-analysis. Fleming, Patrick; Godwin, Marshall // Family Practice;Oct2013, Vol. 30 Issue 5, p485 

    Background. Dietary glycaemic index (GI) is a measure of the postprandial glycaemic response to carbohydrates. Observational studies have found increased triglycerides and decreased high-density lipoprotein levels in patients consuming higher GI foods. Objective. Our aim was to review and...

  • Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Kishi, Taro; Matsuda, Yuki; Iwata, Nakao // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Background: The present study aimed to evaluate cardiometabolic risks [weight gain, blood lipid levels (total cholesterol and triglycerides), blood glucose levels, hemoglobin A1c (HbA1c) levels, and corrected QT interval (QTc) prolongation] associated with the use of blonanserin and perospirone...

  • Comparison of the Peak-to-trough Fluctuation in Plasma Concentration of Long-acting Injectable Antipsychotics and Their Oral Equivalents. Sheehan, John J.; Reilly, Kristin R.; Fu, Dong-Jing; Alphs, Larry // Innovations in Clinical Neuroscience;Jul/Aug2012, Vol. 9 Issue 7/8, p17 

    ABSTRACT; Background: Small peak-to trough drug levels have been suggested to be related to improved tolerability. The aim of this study is to review the steady-state, peak-to trough,plasma-concentration fluctuation of long-acting injectable antipsychotics and equivalent oral...

  • The chronic care model for type 2 diabetes: a systematic review. Baptista, Deise Regina; Wiens, Astrid; Pontarolo, Roberto; Regis, Lara; Torelli Reis, Walleri Christine; Correr, Cassiano Januário // Diabetology & Metabolic Syndrome;1/22/2016, Vol. 8, p1 

    The chronic care model (CCM) uses a systematic approach to restructure health care systems. The aim of this systematic review was to examine studies that evaluated different elements of the CCM in patients with type 2 diabetes mellitus (T2DM) and to assess the influence of the CCM on different...

  • Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly. Guenette, Melanie; Chintoh, Araba; Remington, Gary; Hahn, Margaret // Drugs & Aging;Mar2014, Vol. 31 Issue 3, p159 

    The metabolic side effects of atypical antipsychotics (AAPs) have been widely studied in younger populations, but research investigating these sequelae in the elderly is lacking. This article reviews the available literature examining the use of AAPs in the elderly, evaluating their association...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics